At this point in Cabo's clinical development in mCRPC, it's likely a lot easier to find an oncodoc willing to write a late-stage, refractory salvage prescription for cabo than it is to find an insurer willing to pick up the tab. There are currently many approved therapies that would necessarily take precedence, but I suspect a wink and a nod from the NCCN is not too far off if an appropriately targeted patient population can reasonably be verified.
If I were a late stage bony mets CRPC survivor...with bone mets as my greatest life-threatening morbidity...
I'd be hopeful my doc would at least consider Cabo's obvious utility. The P2 RDT results are inarguably compelling, though not yet sufficient - statistically speaking - for payor commitment.
In the current treatment algorithm, I think low-dose Cabo's a plug & play in post-Alpharadin. JMO.